hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
GSK’s shares have opened higher after sales and profits for the first quarter exceeded expectations.
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
hVIVO PLC FDA Breakthrough and Fast Track for US biotech
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
N4 Pharma PLC (AIM:N4P) siRNA update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
hVIVO PLC (AIM:HVO) Final results
Transformational year with record EBITDA underlining strong operational delivery
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
N4 Pharma’s share price has risen due to positive developments related to Nuvec
N4 Pharma PLC’s (AIM: N4P) shares have risen by more than 7% following the biotech firm’s announcement that it has successfully completed the single loading of EGFR and BCL-2 siRNA
hVIVO PLC (AIM:HVO) Positive results from flu human challenge study
Positive results from influenza human challenge study conducted by hVIVO
hVIVO PLC (AIM:HVO) World Vaccine Congress Presentation
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
hVIVO PLC (AIM:HVO) Omicron human challenge model update
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
4d Pharma PLC (AIM:DDDD) Cancellation of admission to trading on AIM
Leeds, UK, 15 February 2023 – 4D pharma plc (the “Company”) (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class